Thrombate III Market Report 2026

Thrombate III Market Overview

• The Thrombate III market growth in the historic period has been driven by improved diagnosis of clotting disorders, wider adoption of plasma-derived anticoagulant therapies • Market expansion is supported by increasing surgical procedures in high-risk patients, rising demand for personalized anticoagulation management • Growth Driver: Impact Of Increasing Hemophilia Prevalence On The Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Thrombate III Market?

Thrombate III (generic name: antithrombin III [human]) is a prescription medication used to treat or prevent blood clotting disorders in patients with antithrombin III deficiency. It is used primarily in patients with hereditary antithrombin III deficiency to avoid blood clots, especially during high-risk situations such as surgery or childbirth. The main types of indications in thrombate III are surgical procedures and hereditary antithrombin deficiency. Surgical procedures are medical operations performed by trained surgeons to treat or manage diseases, injuries, or conditions through the use of instruments, often involving incisions or alterations to the body. It is distributed through various channels such as hospital pharmacies and online pharmacies, catering to various end users such as adults and geriatrics.

What Is The Thrombate III Market Growth Forecast?

The growth in the forecast period can be attributed to increasing surgical procedures in high-risk patients, rising demand for personalized anticoagulation management, expansion of rare blood disorder treatment programs, advancements in plasma fractionation techniques, growing investments in specialty hematology therapeutics. Major trends in the forecast period include increasing use of antithrombin replacement therapies, growing focus on preventive management of coagulation disorders, expansion of perioperative hemostasis protocols, rising awareness of hereditary antithrombin deficiency, improved plasma-derived product purification.

Global Thrombate III Market Segmentation

1) By Indication: Surgical Procedures, Hereditary Antithrombin Deficiency 2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Thrombate III Market?

The increasing prevalence of hemophilia is expected to propel the growth of the thrombate III market going forward. Hemophilia is a rare genetic disorder where blood doesn't clot properly due to a deficiency in essential clotting factors, leading to prolonged bleeding after injury, surgery, or even spontaneous bleeding into joints or muscles. The prevalence of hemophilia can be attributed to factors such as genetic mutations, family history, and improved diagnosis methods, leading to better detection and reporting. Thrombate III is used in hemophilia treatment to help control bleeding by providing activated antithrombin III, which inhibits clotting factors and prevents excessive bleeding. For instance, in Aoril 2025, according to Pfizer Inc a US-based pharmaceutical and biotechnology corporation, in the 2023/24 period, the UK haemophilia A and B patient population exceeded 11,800 individuals, underscoring a sizable and clinically significant treated population. Therefore, the increased prevalence of hemophilia is driving growth in the thrombate III industry. The rising healthcare infrastructure is expected to propel the growth of the thrombate III market going forward. Healthcare infrastructure refers to the physical facilities, workforce, systems, and resources required to deliver effective and accessible healthcare services. The rise in healthcare infrastructure is due to the aging population and advancements in medical technology, which demand more facilities and innovative treatments. Healthcare infrastructure drives the demand for Thrombate III by ensuring better access to specialized treatments, diagnostic facilities, and skilled healthcare professionals for managing conditions like antithrombin III deficiency. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the rising healthcare infrastructure drives growth in the thrombate III industry. The rising surgical procedures are expected to propel the growth of the thrombate III market going forward. Surgical procedures refer to medical operations or interventions performed by a surgeon or medical professional to treat or diagnose a condition, injury, or disease, often involving making incisions in the body to access and treat internal areas. The rise in surgical procedures can be attributed to advancements in medical technology, an aging population, an increasing prevalence of chronic diseases, improved healthcare access, and greater awareness of treatment options. Thrombate III helps in surgical procedures by providing antithrombin III to prevent excessive blood clotting, particularly in patients with antithrombin III deficiency, reducing the risk of complications such as deep vein thrombosis or pulmonary embolism. For instance, in August 2024, according to the National Library of Medicine a US-based government agency reported that 3.4% global rise in aesthetic procedures, totaling 34.9 million surgical and nonsurgical treatments performed by plastic surgeons in 2023. This includes 15.8 million surgical and 19.1 million nonsurgical procedures worldwide. Therefore, the rising surgical procedures drive growth in the thrombate III industry.

Key Players In The Global Thrombate III Market

Major companies operating in the thrombate iii market are Grifols S.A.

Regional Insights

North America was the largest region in the thrombate III market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Thrombate III Market?

The thrombate III market consists of sales of vials, pre-filled syringes, reconstitution kits, administration kits, and storage and transport kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thrombate III Market Report 2026?

The thrombate iii market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thrombate iii industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.